TC
BMY icon

Trilogy Capital’s Bristol-Myers Squibb BMY Stock Holding History

Trilogy Capital’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$342K Buy
5,935
+281
+5% +$16.1K 0.01% 315
2026
Q1 		$343K Sell
5,654
-262
-4% -$15.3K 0.02% 303
2025
Q4 		$319K Sell
5,916
-280
-5% -$13.5K 0.01% 303
2025
Q3 		$279K Buy
6,196
+1,558
+34% +$72.8K 0.01% 322
2025
Q2 		$215K Sell
4,638
-740
-14% -$36.3K 0.01% 355
2025
Q1 		$328K Sell
5,378
-18,732
-78% -$1.09M 0.02% 268
2024
Q4 		$1.36M Sell
24,110
-42,012
-64% -$2.35M 0.07% 164
2024
Q3 		$3.42M Buy
66,122
+419
+0.6% +$19.7K 0.17% 93
2024
Q2 		$2.73M Buy
65,703
+5,219
+9% +$234K 0.15% 112
2024
Q1 		$3.28M Buy
60,484
+7,678
+15% +$391K 0.19% 90
2023
Q4 		$2.71M Buy
52,806
+3,181
+6% +$167K 0.17% 102
2023
Q3 		$2.88M Buy
49,625
+42,287
+576% +$2.59M 0.2% 74
2023
Q2 		$475K Buy
7,338
+1,671
+29% +$112K 0.03% 175
2023
Q1 		$393K Buy
5,667
+1,108
+24% +$78.1K 0.03% 170
2022
Q4 		$328K Buy
4,559
+853
+23% +$64.3K 0.02% 189
2022
Q3 		$263K Sell
3,706
-6
-0.2% -$435 0.02% 157
2022
Q2 		$286K Buy
3,712
+221
+6% +$16.8K 0.02% 135
2022
Q1 		$255K Buy
+3,491
New +$234K 0.02% 155
2018
Q4 		– Sell
-523
Closed -$32K – 188
2018
Q3 		$32K Buy
523
+142
+37% +$8.43K ﹤0.01% 230
2018
Q2 		$21K Buy
381
+81
+27% +$4.38K ﹤0.01% 244
2018
Q1 		$19K Buy
+300
New +$19.3K ﹤0.01% 225

Other funds holding BMY

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
ORIO
Old Republic International (ORI) Chicago, Illinois $2.67B AUM 26.94% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return

Trilogy Capital's BMY Position: Q2 2026 in Review

Trilogy Capital increased its Bristol-Myers Squibb (BMY) stake by 5% in Q2 2026, buying an estimated $16.1K and bringing the position to 5,935 shares worth $342K. The position accounts for 0.01% of the portfolio, ranked #315.

Trilogy Capital first reported a position in BMY in Q1 2018 and has held it in 21 quarters since. The position peaked at $3.42M in Q3 2024. 440 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Trilogy Capital held 5,935 shares of Bristol-Myers Squibb worth $342K as of Q2 2026.
  • Trilogy Capital bought 281 Bristol-Myers Squibb shares in Q2 2026, an estimated $16.1K.
  • Bristol-Myers Squibb made up 0.01% of Trilogy Capital's portfolio in Q2 2026, its #315 holding.
  • Trilogy Capital first reported a position in Bristol-Myers Squibb in Q1 2018 and has held it in 21 quarters since.
  • Trilogy Capital's Bristol-Myers Squibb position peaked at $3.42M in Q3 2024.
  • 440 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Trilogy Capital's 13F filing for Q2 2026, filed 6 Jul 2026.